Primairy prevention of atopic disease by perinatal administration of probiotics.

Gepubliceerd: 09-09-2005 Laatst bijgewerkt: 18-08-2022

Administration of probiotics to pregnant women from an atopic family and subsequently to their high-risk newborns results in prevention of the incidence of or in a decrease of the severity of atopic disease during infancy.

Ethische beoordeling	Positief advies
Status	Werving gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON26444

Bron
Nationaal Trial Register

Verkorte titel
PANDA

Aandoening

A randomised double-blind intervention study in pregnant mothers from atopic families and in their newborns.

Ondersteuning

Primaire sponsor: Wilhelmina Children's Hospital, PO box 85090, 3508 AB Utrecht, The Netherlands.

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

Incidence and severity of atopic disease at the age of 2 years.

Toelichting onderzoek

Achtergrond van het onderzoek

Inclusion of pregnant mothers from atopic families has ended. Around January first 2006 all children are born. Results on cord blood analysis are expected in spring of 2006. Clinicial data at the age of 3 months are expected just before the summer of 2006.

Doel van het onderzoek

Administration of probiotics to pregnant women from an atopic family and subsequently to their high-risk newborns results in prevention of the incidence of or in a decrease of the severity of atopic disease during infancy.

Onderzoeksproduct en/of interventie

A combination of probiotics (Lact.Lactis, B.Bifidum, B.Infantum), each 1000 milion daily, added to the the formula used.

Contactpersonen

Publiek

University Medical Center Utrecht (UMCU),
Wilhelmina Children's Hospital,
P.O. Box 85090
M.O. Hoekstra
Lundlaan 6
Utrecht 3508 AB
The Netherlands
+31 (0)30 2504001

Wetenschappelijk

University Medical Center Utrecht (UMCU),
Wilhelmina Children's Hospital,
P.O. Box 85090
M.O. Hoekstra
Lundlaan 6
Utrecht 3508 AB
The Netherlands
+31 (0)30 2504001

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

Pregnant mothers were included if either they themselves or their husband plus a sibling suffered from present or past atopic disease.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. Maternal use of immunomodulatory drugs during pregnancy;
2. The use of probiotics.

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Blindering:	Dubbelblind
Controle:	Placebo

Deelname

Nederland

Status:	Werving gestart
(Verwachte) startdatum:	01-01-2004
Aantal proefpersonen:	120
Type:	Verwachte startdatum

Ethische beoordeling

Positief advies

Datum:	09-09-2005

Soort: Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL285
NTR-old	NTR323
Ander register	: N/A
ISRCTN	ISRCTN52995544

Resultaten

Samenvatting resultaten
N/A